Can maintenance cyclosporine be used in psoriasis without decreasing renal function?

Area of Science:

• Nephrology
• Dermatology
• Pharmacology

Background:

• Cyclosporine is an immunosuppressive drug used in treating psoriasis.
• Nephrotoxicity is a known potential side effect of cyclosporine therapy.
• Dose dependency of cyclosporine's nephrotoxicity is established.

Purpose of the Study:

• To evaluate the risk of nephrotoxicity in psoriasis patients undergoing cyclosporine treatment.
• To establish guidelines for monitoring renal function during cyclosporine therapy for psoriasis.
• To determine safe dosage thresholds and monitoring frequencies for cyclosporine in psoriasis management.

Main Methods:

• Review of existing literature on cyclosporine-induced nephrotoxicity in psoriasis.
• Analysis of dose-response relationship between cyclosporine and renal function.
• Recommendations for monitoring serum creatinine, urea nitrogen, blood pressure, and glomerular filtration rate (GFR).

Main Results:

• Nephrotoxicity is unlikely at cyclosporine doses below 5 mg/kg/d in healthy psoriasis patients.
• Regular monitoring of renal function (urea nitrogen/creatinine) and blood pressure is crucial for long-term protocols.
• Yearly GFR measurement is advised for otherwise healthy psoriasis patients, particularly the elderly or those with diabetes.

Conclusions:

• Low-dose cyclosporine protocols for psoriasis do not show convincing evidence of irreversible renal dysfunction.
• Cyclosporine, even at low doses, requires careful monitoring; it is not considered entirely safe.
• Proposed monitoring schedule includes GFR at 3, 6, and 12 months, with more frequent checks and dose adjustments if serum creatinine increases by over 30%.